3. Results
Breast cancer, cardiotoxic, sarcoma
MAY, BREAST CANCER, SARCOMA, BILATERAL BREAST CANCER
From May 2019 to January 2022, we screened 120 patients who were referred for cardiotoxic risk assessment before planned anthracycline treatment. All were females with a median age of 48 years. A total of 66 patients were not eligible for the study, for the following reasons: 36 patients had resting HR < 75 BPM; 19 patients were using ACEIs/ARBs or BBs; 11 had poor echogenicity. Furthermore, five patients refused to participate in the study.We randomised the remaining 48 patients. A total of 21 patients were randomly assigned to the ivabradine group and 27 patients to the control group. During the study, three ivabradine group patients were lost to follow-up. The follow-up was completed in August 2022. The diagram of the study is presented in Breast cancer was diagnosed in 46 patients (20 on the right side, 25 on the left side, and 1 had bilateral breast cancer); 2 patients presented with sarcoma. The main anthracyclines prescribed were doxorubicin and epirubicin, with median cumulative doses of 242 (180–375) mg/mThe baseline characteristics of the patients were statistically balanced between the groups. Patients’ baseline characteristics are shown in 